CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

被引：45

作者：

Ghosh, Arnab ^{[1
]}

Mailankody, Sham ^{[2
]}

Giralt, Sergio A. ^{[3
,4
]}

Landgren, C. Ola ^{[2
]}

Smith, Eric L. ^{[2
,4
]}

Brentjens, Renier J. ^{[4
,5
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Hematol Oncol BMT Fellowship Program, 1275 York Ave, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Adult BMT Serv, 1275 York Ave, New York, NY 10021 USA

[4] Mem Sloan Kettering Canc Ctr, Cellular Therapeut Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 09期

关键词：

Multiple myeloma; chimeric antigen receptors; BCMA; hematopoietic cell transplantation; CAR; immunotherapy; TCR; DONOR LYMPHOCYTE INFUSIONS; B-CELL; MATURATION ANTIGEN; PLASMA-CELLS; MHC BARRIERS; BONE-MARROW; RECEPTOR; TRANSPLANTATION; CANCER; CD38;

D O I：

10.1080/10428194.2017.1393668

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

While recent progress has been made in the management of multiple myeloma, it remains a highly fatal malignancy especially among patients with relapsed-refractory disease. Immunotherapy with adoptive T cells targeting myeloma-associated antigens are at various stages of development and have brought about a new hope for cure. This is a review on the emerging field of adoptively transferred engineered T cell based approaches, with an in-depth focus on chimeric antigen receptors (CAR) targeting multiple myeloma. The recent results from CAR T cells targeting B cell maturation antigen are encouraging but eventual resistance to the CAR T cell therapies remain problematic. With newer approaches in therapies for multiple myeloma, the role of transplantation is evolved to form a platform for T cell therapies.

引用

页码：2056 / 2067

页数：12

共 50 条

[21] Drug Development for Alzheimer's Disease: Where Are We Now and Where Are We Headed?
Sabbagh, Marwan N.
[J]. AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, 2009, 7 (03): : 167 - 185
[22] Microbiome-Based Diagnostics for Disease: Where Are We Now and Where Are We Headed?
Yarbrough, Melanie L.
Dumm, Rebekah E.
Bry, Lynn
Kelly, Brendan J.
Schwartz, Drew
Uberoi, Aayushi
[J]. CLINICAL CHEMISTRY, 2024, 70 (06) : 792 - 797
[23] Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review
Kent, Collin L.
McDuff, Susan G. R.
Salama, Joseph K.
[J]. ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (05) : 5954 - 5968
[24] ASTM's bulk method: Where are we, where are we headed, where should we be headed?
Stewart, IM
[J]. ADVANCES IN ENVIRONMENTAL MEASUREMENT METHODS FOR ASBESTOS, 1999, 1342 : 122 - 126
[25] HAEMATOLOGICAL CANCER Where are we now with the treatment of multiple myeloma?
Morgan, Gareth J.
Rasche, Leo
[J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (08) : 461 - 462
[26] Public reporting on cardiac electrophysiology procedures and outcomes: where are we now and where are we headed?
Samuel M. Kim
Jim W. Cheung
[J]. Journal of Interventional Cardiac Electrophysiology, 2019, 56 : 137 - 141
[27] Impact of the Internet on collection development: where are we now? Where are we headed? An informal study
Intner, SS
[J]. LIBRARY COLLECTIONS ACQUISITIONS & TECHNICAL SERVICES, 2001, 25 (03): : 307 - 322
[28] Public reporting on cardiac electrophysiology procedures and outcomes: where are we now and where are we headed?
Kim, Samuel M.
Cheung, Jim W.
[J]. JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2019, 56 (02) : 137 - 141
[29] The coming of age of neutrophil extracellular traps in thrombosis: Where are we now and where are we headed?
Van Bruggen, Stijn
Martinod, Kimberly
[J]. IMMUNOLOGICAL REVIEWS, 2023, 314 (01) : 376 - 398
[30] Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Thanendrarajan, Sharmilan
Davies, Faith E.
Morgan, Gareth J.
Schinke, Carolina
Mathur, Pankaj
Heuck, Christoph J.
Zangari, Maurizio
Epstein, Joshua
Yaccoby, Shmuel
Weinhold, Niels
Barlogie, Bart
van Rhee, Frits
[J]. IMMUNOTHERAPY, 2016, 8 (03) : 367 - 384

← 1 2 3 4 5 →